|
|
|
|
3 Faculty of Nutrition and Department of Animal Science, Texas A&M University, College Station, TX 77843; 4 Cardiovascular Research Institute and Department of Systems Biology and Translational Medicine, Texas A&M Health Science Center, College Station, TX 77843; 5 USDA-Agricultural Research Service, South Central Agricultural Research Laboratories, Lane, OK 74555; 6 Department of Food Science and Human Nutrition, Michigan State University, East Lansing, MI 48824; and 7 Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843
* To whom correspondence should be addressed. E-mail: g-wu{at}tamu.edu.
| ABSTRACT |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Growing evidence shows that physiological levels of NO play an important role in regulating the oxidation of energy substrates, insulin sensitivity, and hemodynamics in animals and humans (6). In addition, NO is a key mediator of the immune response (7) and neurological function (8). NO is synthesized from L-arginine by tetrahydrobiopterin (BH4)-dependent NO synthase (9), underscoring a crucial role for this amino acid in maintaining health and treating a wide array of chronic diseases. In support of this notion, recent findings indicate that dietary supplementation with L-arginine reduced plasma levels of glucose in chemically induced diabetic rats (10–12) and the Zucker diabetic fatty (ZDF) rat (a genetically obese animal model of NIDDM) (13), decreased excess fat mass in ZDF rats (13) and diabetic patients (14), and improved vascular reactivity in diabetic rats (2), obese hamsters (15), and hypercholesterolemic humans (16).
Because arginine has a strong alkaline property in physiological solutions, its HCl salt or a mixture with acidic organic substances is generally used for administration into animals (17) or humans (18) to prevent an acid-base imbalance. However, high oral doses of arginine (> 9 g/d) is associated with nausea, gastrointestinal discomfort, and diarrhea in some subjects (19,20). Also, oral administration of arginine is currently not recommended for patients with myocardial infarction because of a possible increase in mortality (21), likely due to an abrupt increase in NO production. A solution to this potentially severe problem associated with dietary arginine supplementation may be the alternative use of L-citrulline, a neutral amino acid and an effective precursor for L-arginine synthesis (22). L-Citrulline is unusually rich in watermelon (23) and we recently found that chronic consumption of this functional food was effective in increasing plasma concentrations of arginine in healthy humans (24). However, there is a paucity of literature regarding a role for watermelon consumption in improving health in obese or diabetic subjects.
We hypothesized that dietary supplementation with watermelon pomace juice might be beneficial for enhancing arginine availability and ameliorating the metabolic syndrome in NIDDM. This hypothesis was tested in the present study using the ZDF rat as an animal model.
| Materials and Methods |
|---|
|
|
|---|
Preparation of watermelon pomace juice and its amino acid concentrations. We purchased seedless watermelons from a local source in East Lansing, Michigan. Pomace was prepared from the watermelons using a rack and cloth hydraulic press. Immediately before use, the pomace was squeezed using a juice maker. The resulting juice was filtered through a fine screen (03–250/50 NITEX, SefarFiltration) to obtain fluid, which was then added to drinking water for rats. Concentrations of carbohydrates, protein, and fat in the watermelon pomace juice were 24, 0.87, and 0.45 g/L, respectively, as determined using the proximate analysis (25). Concentrations of free amino acids in the watermelon pomace juice (mg/L), analyzed using HPLC methods (13), were as follows: citrulline, 2014; arginine, 1150; aspartate, 66; glutamate, 17; asparagine, 45; serine, 60; glutamine, 172; histidine, 88; glycine, 18; threonine, 34; alanine, 32; tyrosine, 37; tryptophan, 48; methionine, 39; valine, 78; phenylalanine, 89; isoleucine, 87; leucine, 79; ornithine, 18; lysine, 75; cysteine, 62; and proline, 74. Citrulline plus arginine accounted for 71% of total free amino acids (4.5 g/L) in the watermelon pomace juice.
Experimental design and animals. Male ZDF rats (8 wk old) were obtained from Charles River and had free access to drinking water and a Purina 5008 diet (13) throughout the study. This nonpurified diet contained 23.5% crude protein, 6.0% fat, 34.9% starch, 2.6% sucrose, 0.5% glucose plus fructose, 6.8% minerals, 3.8% fiber, and 17,364 kJ gross energy/kg. Alanine content in the diet was 1.39%, arginine was 1.44%, and lysine was 1.40%. Rats were housed in a temperature- and humidity-controlled facility on a 12-h-light:12-h-dark cycle.
At 9 wk of age, rats were assigned randomly to receive drinking water (distilled and deionized water) containing 0.0% or 0.2% L-arginine (as 0.24% L-arginine-HCl), 63% watermelon pomace juice, 0.01% lycopene, or 0.05% citrus pectin (n = 6 per treatment). L-Arginine was used as a positive control. The dose of watermelon pomace juice was chosen to provide 0.2% L-citrulline plus L-arginine (this study). Because almost all dietary L-citrulline is converted into arginine in animals (9), the dose of watermelon pomace juice was chosen to provide L-arginine similar to L-arginine intake from drinking water by arginine-supplemented ZDF rats. The doses of lycopene and citrus pectin were selected to mimic those in 63% watermelon pomace juice (26). The drinking water was changed daily at 0900. We measured body weights and food intakes of rats daily. At the end of the 4-wk dietary supplementation, rats were killed to obtain tissues. On the day before rats were killed, tail venous blood samples (0.2 mL) were obtained at 1200 (6 h after feeding) from unanesthetized rats, as described by Wu (27). In the morning of the next day, 6 h after feeding, rats were killed with an effective dose of CO2 and cardiac blood samples, aorta, and other tissues were obtained. Blood samples were centrifuged at 10,000 x g for 1 min to obtain serum, aorta was placed in PBS on wet ice, and other tissues were frozen in liquid nitrogen. This study was approved by Texas A&M University Animal Care and Use Committee.
Biochemical analysis. Serum samples from the tail vein were analyzed for amino acids, glucose, nitrite and nitrate (NOx), oxidation products of NO, and lipids using established methods (13,17,28). Cardiac serum samples were used for the determination of methylarginines (inhibitors of NO synthase), homocysteine, insulin, and growth hormone, as we previously described (12,13). Methylarginines and homocysteine are independent risk factors for cardiovascular disease (18).
Determination of NO synthase activity, GTP cyclohydrolase-I activity, and BH4 concentrations in the heart. The enzymatic activities of NO synthase (both constitutive and inducible) and GTP cyclohydrolase-I in the heart (as a vascular tissue) were determined using radiochemical and HPLC methods, respectively, as described by Meininger and Wu (28). Concentrations of BH4 were measured by HPLC after oxidation of samples under acidic and alkaline conditions (28).
Measurement of endothelium-dependent relaxation in aorta. The endothelium-dependent relaxation of thoracic aortic rings was determined in the presence of 10–9 to 10–5 mol/L acetylcholine and 0 or 0.1 mmol/L NG-monomethyl-L-arginine (an inhibitor of NO synthase), as described by Heaps et al. (29). In all rings, NO-mediated relaxation was verified at the end of the experiment using 100 µmol/L sodium nitroprusside, a spontaneous NO donor (30).
Calculation and statistical analysis.
Results are expressed as means ± SEM. Combustion energy values of arginine (21.45 kJ/g), protein (22.6 kJ/g), carbohydrate (17.2 kJ/g), and fat (39.3 kJ/g) were used to calculate energy intake from the drinking water (12). Data on body and tissue weights, nutrient intakes, metabolite concentrations, and enzyme activities were analyzed by 1-way ANOVA. Data on aortic vessel relaxation were analyzed using 2-way ANOVA for repeated measurements. Differences among the means of treatment groups were determined by the Student-Newman-Keuls test. All statistical analyses were performed using SAS software (SAS Institute). P
0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
Endothelial dysfunction is a major risk factor that contributes to high rates of morbidity and mortality in NIDDM (5). Aortic rings from all groups of ZDF rats exhibited similar relaxation (
93%) in response to sodium nitroprusside (a spontaneous donor of NO), suggesting that NO signaling pathways are intact in vascular smooth cells. Interestingly, when NO synthesis was blocked by NG-monomethylarginine, vessel reactivity was minimal (< 8% relaxation) and did not differ among all the groups of ZDF rats. This result demonstrates that acetylcholine-induced relaxation in aortic rings was primarily mediated by NO and that NO-independent vessel reactivity was likely not affected by dietary supplementation with L-arginine or watermelon pomace juice. In contrast, compelling evidence shows that endothelium-dependent relaxation is impaired in obese ZDF rats compared with lean Zucker rats (32,33). Thus, increasing NO availability would be beneficial for improving hemodynamics and, therefore, preventing and treating cardiovascular disease in ZDF rats and perhaps humans.
We reported that the endothelial synthesis of NO is impaired in the Bio-Breeding rat (a spontaneous model of type I diabetes) and the ZDF rat due to a deficiency of GTP cyclohydrolase-I (30,34), the first and rate-controlling enzyme for the de novo synthesis of BH4 (an essential cofactor for NO synthase). Increasing the availability of BH4 through either the transfer of the GTP cyclohydrolase-I gene or addition of sepiapterin (an effective precursor of BH4) restored NO synthesis in endothelial cells (12,30). The GTP cyclohydrolase-I gene therapy also normalized aortic vessel reactivity in both Bio-Breeding and ZDF rats (30). Notably, results from this study indicate that endothelium-dependent relaxation was markedly improved in ZDF rats that received chronic supplementation with either watermelon pomace juice or L-arginine (Fig. 1), in association with reduced serum concentrations of risk factors for vascular dysfunction (including glucose, free fatty acids, methylarginines, and homocysteine) (Tables 2–5). In contrast, dietary supplementation with lycopene and pectin, 2 other substances that are present in watermelon pomace juice (26), had no effect on all the measured parameters in ZDF rats. These results suggest that the beneficial effect of watermelon pomace juice as a functional food on vascular function results from its provision of citrulline and arginine.
In endothelial cells, L-arginine itself is not limiting for NO synthase, because intracellular concentrations of arginine (0.5–1.5 mmol/L) are well above the Km value for the nitrogenous substrate (
3 µmol/L) (22). L-Arginine did not affect expression of NO synthase-3 protein in endothelial cells (35). However, physiological concentrations of L-arginine stimulates GTP cyclohydrolase-I expression in these cells (35), therefore increasing the synthesis and availability of BH4 that is required for maximal NO generation and vessel relaxation (30). Consistent with this observation, we found that dietary supplementation with L-arginine or watermelon pomace juice did not affect the amount of NO synthase protein (as indicated by no change in its enzymatic activity measured under optimal conditions) in the heart of ZDF rats (Table 6). However, the arginine treatment enhanced GTP cyclohydrolase-I activity and BH4 concentrations in this vascular tissue (Table 6).
Another novel and interesting result from this study is that dietary supplementation with either watermelon pomace juice or L-arginine increased the mass of brown adipose tissue and reduced the mass of subcutaneous and retroperitoneal fat pads in ZDF rats (Table 2). Brown adipose tissue is rich in mitochondria, where fatty acid and glucose oxidation results in the production of heat rather than ATP because of the presence of uncoupling protein-1 (6). Increased brown adipose tissue brought about by the treatment with watermelon pomace juice or L-arginine is expected to augment the oxidation of fatty acids and glucose in this tissue, thereby reducing their plasma concentrations and use for fat synthesis in white adipose tissue. Our finding is consistent with the recent discovery that NO stimulates mitochondrial biogenesis in various tissues, including brown adipose tissue (8). Additionally, L-arginine enhanced gene expression of peroxisome proliferator-activated receptor
coactivator-1
(13), a master regulator of oxidative phosphorylation and mitochondrial biogenesis in diverse cell types (8), therefore reducing the mass of white adipose tissue in ZDF rats (Table 2).
Chronic consumption of watermelon is a safe and effective alternative to oral administration of L-arginine in raising its plasma levels in healthy subjects (24) and may represent a novel and useful strategy for the management of obesity and diabetes. Provision of citrulline from watermelon also offers a unique advantage over the enteral supply of L-arginine for the following reasons. First,
40% of dietary L-arginine is catabolized by the intestinal tissues of adult humans and other mammals in the first pass (36). In contrast, citrulline undergoes limited degradation in enterocytes of postweaning animals due to a low activity of argininosuccinate synthase in the cells (37). Thus, on the same equal molar basis, the entry of dietary citrulline into the portal circulation is much greater than that of dietary arginine in adults. Second, there is little uptake of circulating citrulline by liver and, therefore, nearly all the citrulline absorbed from the small intestine bypasses the liver and enters the systemic circulation (38). Third, in mammals, the synthesis of arginine from citrulline is the only pathway for its utilization by extrahepatic tissues, including predominantly kidneys as well as other tissue and cell types (e.g. heart, brain, macrophages, and endothelial cells) (9). Indeed, the vascular effects of dietary supplementation with 63% watermelon pomace juice were equivalent to those brought about by supplementation with 0.2% L-arginine in ZDF rats (Fig. 1). Thus, watermelon may be a functional food for ameliorating the metabolic syndrome of NIDDM. Future studies are warranted to determine the effect of watermelon consumption on human subjects with obesity and diabetes.
In conclusion, results of this study demonstrate for the first time to our knowledge a beneficial effect of oral administration of watermelon pomace juice on increasing the mass of brown adipose tissue, reducing excess white fat mass and serum concentrations of risk factors for cardiovascular disease, and enhancing NO-dependent vessel reactivity in ZDF rats. Consumption of this functional food may represent a potentially novel and useful strategy for the dietary management of the metabolic syndrome in NIDDM and obesity.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
2 G. Wu, J. K. Collins, P. Perkins-Veazie, M. Siddiq, K. Dolan, K. A. Kelly, C. L. Heaps, and C. J. Meininger, no conflicts of interest. ![]()
8 Abbreviations used: BH4, tetrahydrobiopterin; NIDDM, noninsulin-dependent diabetes mellitus; NO, nitric oxide; NOx, oxidation products of nitric oxide; ZDF, Zucker diabetic fatty. ![]()
Manuscript received 23 July 2007. Initial review completed 4 September 2007. Revision accepted 2 October 2007.
| LITERATURE CITED |
|---|
|
|
|---|
1. American Diabetes Association. About diabetes. Dallas; 2007.
2. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes. Hypertension. 1998;31:1047–60.
3. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28:2289–304.
4. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OAJ, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2006;49:351–9.[Medline]
5. Johnson JA, Pohar SL, Majumdar SR. Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study. Diabetes Care. 2006;29:2403–8.
6. Jobgen WS, Fried SK, Fu WJ, Meininger CJ, Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J Nutr Biochem. 2006;17:571–88.[Medline]
7. Li P, Yin YL, Li DF, Kim SW, Wu G. Amino acids and immune function. Br J Nutr. 2007;98:237–52.[Medline]
8. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem. 2006;97:1676–89.[Medline]
9. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1–17.[Medline]
10. Miguez I, Marino G, Rodriguez B, Taboada C. Effects of dietary L-arginine supplementation on serum lipids and intestinal enzyme activities in diabetic rats. J Physiol Biochem. 2004;60:31–8.[Medline]
11. Mendez JD, Balderas F. Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in diabetic rats. Biochimie. 2001;83:453–8.[Medline]
12. Kohli R, Meininger CJ, Haynes TE, Yan W, Self JT, Wu G. Dietary L-arginine supplementation enhances endothelial nitric oxide synthesis in streptozotocin-induced diabetic rats. J Nutr. 2004;134:600–8.
13. Fu WJ, Haynes TE, Kohli R, Hu J, Shi W, Spencer TE, Carroll RJ, Meininger CJ, Wu G. Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr. 2005;135:714–21.
14. Lucotti P, Setola E, Monti LD, Galluccio E, Costa S, Sandoli EP, Fermo I, Rabaiotti G, Gatti R, et al. Beneficial effect of a long-term oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab. 2006;291:E906–12.
15. Popov D, Costache G, Georgescu A, Enache M. Beneficial effects of L-arginine supplementation in experimental hyperlipemia-hyperglycemia in the hamster. Cell Tissue Res. 2002;308:109–20.[Medline]
16. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248–53.[Medline]
17. Wu G, Bazer FW, Cudd TA, Jobgen WS, Kim SW, Lassala A, Li P, Matis JH, Meininger CJ, et al. Pharmacokinetics and safety of arginine supplementation in animals. J Nutr. 2007;137:S1673–80.
18. Maxwell AJ, Cooke JP. L-Arginine: its role in cardiovascular therapy. In: Loscalzo J, Vita JA, editors, Nitric oxide and the cardiovascular system. Totowa (NJ): Humana Press; 2001. p. 547–85.
19. Tangphao O, Chalon S, Moreno H, Hoffman BB, Blaschke TF. Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia. Clin Sci. 1999;96:199–207.[Medline]
20. Evans RW, Fernstrom JD, Thompson J, Morris SM, Kuller LH. Biochemical responses of healthy subjects during dietary supplementation with L-arginine. J Nutr Biochem. 2004;15:534–9.[Medline]
21. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin MI, Forman S, Ernst KV, Kelemen MD, Townsend SN, et al. L-arginine therapy in myocardial infarction. The Vascular Interaction with Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA. 2006;295:58–64.
22. Wu G, Meininger CJ. Arginine nutrition and cardiovascular function. J Nutr. 2000;130:2626–9.
23. Rimando AM, Perkins-Veazie PM. Determination of citrulline in watermelon rind. J Chromatogr A. 2005;1078:196–200.[Medline]
24. Collins JK, Wu G, Perkins-Veazie P, Spears K, Claypool PL, Baker RA, Clevidence BA. Watermelon consumption increases plasma arginine concentrations in adults. Nutrition. 2007;23:261–6.[Medline]
25. Wu G, Ott TL, Knabe DA, Bazer FW. Amino acid composition of the fetal pig. J Nutr. 1999;129:1031–8.
26. Edwards AJ, Vinyard BT, Wiley ER, Brown ED, Collins JK, Perkins-Veazie P, Baker RA, Clevidence BA. Consumption of watermelon juice increases plasma concentrations of lycopene and beta-carotene in humans. J Nutr. 2003;133:1043–50.
27. Wu G. Nitric oxide synthesis and the effect of aminoguanidine and NG-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes. 1995;44:360–4.[Abstract]
28. Meininger CJ, Wu G. Regulation of endothelial cell proliferation by nitric oxide. Methods Enzymol. 2002;352:280–95.[Medline]
29. Heaps CL, Sturek M, Rapps JA, Laughlin MH, Parker JL. Exercise training restores adenosine-induced relaxation in coronary arteries distal to chronic occlusion. Am J Physiol Heart Circ Physiol. 2000;278:H1984–92.
30. Meininger CJ, Cai S, Parker JL, Channon KM, Kelly KA, Becker EJ, Wood MK, Wade LA, Wu G. GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J. 2004;18:1900–2.
31. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med. 1983;173:68–75.[Medline]
32. Frisbee JC, Stepp DW. Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. Am J Physiol Heart Circ Physiol. 2001;281:H1304–11.
33. Schwaninger RM, Sun H, Mayhan WG. Impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type II diabetic rats. Life Sci. 2003;73:3415–25.[Medline]
34. Meininger CJ, Marinos RS, Hatakeyama K, Martinez-Zaguilan R, Rojas JD, Kelly K, Wu G. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic BB rat is due to tetrahydrobiopterin deficiency. Biochem J. 2000;349:353–6.[Medline]
35. Wu G, Kelly KA, Hatakeyama K, Meininger CJ. Regulation of endothelial tetrahydrobiopterin synthesis by L-arginine. In: Thony B, Blau N, editors. Pterins, folates, and neurotransmitters in molecular medicine. Heilbronn (Germany): SPS Verlagsgesellschaft mbh; 2004. p. 54–9.
36. Wu G. Intestinal mucosal amino acid catabolism. J Nutr. 1998;128:1249–52.
37. Wu G. Urea synthesis in enterocytes of developing pigs. Biochem J. 1995;312:717–23.[Medline]
38. Morris SM Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002;22:87–105.[Medline]
This article has been cited by other articles:
![]() |
J. L. Nall, G. Wu, K. H. Kim, C. W. Choi, and S. B. Smith Dietary Supplementation of L-Arginine and Conjugated Linoleic Acid Reduces Retroperitoneal Fat Mass and Increases Lean Body Mass in Rats J. Nutr., July 1, 2009; 139(7): 1279 - 1285. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lassala, F. W. Bazer, T. A. Cudd, P. Li, X. Li, M. C. Satterfield, T. E. Spencer, and G. Wu Intravenous Administration of L-Citrulline to Pregnant Ewes Is More Effective Than L-Arginine for Increasing Arginine Availability in the Fetus J. Nutr., April 1, 2009; 139(4): 660 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jobgen, C. J. Meininger, S. C. Jobgen, P. Li, M.-J. Lee, S. B. Smith, T. E. Spencer, S. K. Fried, and G. Wu Dietary L-Arginine Supplementation Reduces White Fat Gain and Enhances Skeletal Muscle and Brown Fat Masses in Diet-Induced Obese Rats J. Nutr., February 1, 2009; 139(2): 230 - 237. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||